Prescription drug · ANDA
Milrinone Lactate in 5% Dextrose NDC 70069-873
Milrinone lactate .2 mg/mL · Injection, Solution · Intravenous · Somerset Therapeutics, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70069-873-10 | 70069087310 | 10 POUCH in 1 CASE (70069-873-10) / 1 BAG in 1 POUCH (70069-873-01) / 200 mL in 1 BAGMarketed from Mar 25, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Milrinone Lactate in 5% Dextrose
- Generic name (nonproprietary)
- milrinone lactate in 5% dextrose
- Active ingredients
- Milrinone lactate — .2 mg/mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- Somerset Therapeutics, LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 219170
- Marketing start
- Listing expires
- Other FDA classes
- Phosphodiesterase 3 Inhibitors (Mechanism)
- Identifiers
- Product ID 70069-873_27a19fc1-5e18-44e1-957d-d90f18dedc54SPL ID 27a19fc1-5e18-44e1-957d-d90f18dedc54SPL set ID 27a19fc1-5e18-44e1-957d-d90f18dedc54RxCUI 1791840, 1791842UNII 9K8XR81MO8UPC 0370069873014, 0370069872017
- Pharmacologic class
- Phosphodiesterase 3 Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N470069087310followed by a unit qualifier and the quantityPackage 70069-0873-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 219170
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Milrinone Lactate in 5% Dextrose | Milrinone lactate .2 mg/mL | Injection, SolutionIntravenous | Caplin Steriles Limited | 65145-177 |
| Milrinone Lactate in 5% Dextrose | Milrinone lactate .2 mg/mL | Injection, SolutionIntravenous | Caplin Steriles Limited | 65145-176 |
| Milrinone Lactate in 5% Dextrose | Milrinone lactate .2 mg/mL | Injection, SolutionIntravenous | Somerset Therapeutics, LLC | 70069-872 |